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During 1997–1999, a total of 70,067 isolates (6631 Pseudomonas aeruginosa isolates) were analyzed in the
SENTRY program by geographic region and body site of infection. The respiratory tract was the most common
source of P. aeruginosa. P. aeruginosa isolation rates increased during the study interval. Europe was the only
region to show a significant decline in b-lactam and aminoglycoside susceptibility rates. There was a reduction
in the rates of susceptibility of Canadian isolates to imipenem and of Latin American isolates to meropenem.
A total of 218 multidrug-resistant P. aeruginosa isolates (MDR-PSA; resistant to piperacillin, ceftazidime,
imipenem, and gentamicin) were observed; MDR-PSA occurrence rates (percentages of all isolates) ranged
from 8.2% (Latin America) to 0.9% (Canada). No antimicrobial inhibited 150% of MDR-PSA strains. Molecular
characterization of selected, generally resistant strains was performed. Isolates showing unique ribogroups
were found in Europe, Latin America, and the United States, but clonal spread was documented in several
medical centers.
Pseudomonas aeruginosa is a cosmopolitan gram-neg-
ative aerobic bacillus [1] isolated from soil, water,
plants, and animals, including humans. It is occasion-
ally pathogenic for plants as well as animals. The min-
imal nutritional requirements of P. aeruginosa, its tol-
erance of a wide variety of physical conditions, and its
relative resistance to antimicrobial agents contribute to
its ecologic success and to its role as an effective op-
portunistic pathogen. It rarely causes disease in healthy
persons, although it is a common human saprophyte.
In most cases the disease process begins with some
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alteration of normal host defenses. This may involve a
disruption in the integrity of physical barriers to bac-
terial invasion, such as intravenous lines, urinary cath-
eters, or endotracheal tubes. In other instances, there
is an underlying dysfunction of specific host-defense
mechanisms, such as neutropenia or iatrogenic im-
munosuppression [2, 3].
The existence of multiple pathogenic mechanisms in
such diverse diseases caused by P. aeruginosa must be
assumed [2]. Cellular injury caused by endotracheal
intubation may also play a role in the initial attachment
of P. aeruginosa to epithelial cells in the respiratory tract
[4]. In addition to factors involved in the virulence of
P. aeruginosa, its resistance to antimicrobials contrib-
utes to its role as an effective opportunistic pathogen.
Resistance to antipseudomonal b-lactams has been well
described, and resistance to recent-generation cepha-
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losporins, monobactams, and carbapenems is becoming a dis-
turbing clinical problem.
b-Lactam resistance is due to a variety of mechanisms; AmpC
b-lactamase production [5–7], extended-spectrum b-lacta-
mases [8], including carbapenemases [9–12], a barrier to dif-
fusion at the outer membrane, and efflux mechanisms are
among those described [13–24]. Loss of permeability [25] and
active antimicrobial efflux may affect other types of drugs such
as aminoglycosides or quinolones [26, 27]. This may be com-
plemented with alterations in DNA gyrase [28] and the presence
of aminoglycoside-modifying enzymes, leading to the emer-
gence of multidrug-resistant P. aeruginosa (MDR-PSA) [13, 18,
29–39] against which there are very few therapeutic options,
such as polymyxins [30, 40–42].
P. aeruginosa is primarily a nosocomial pathogen [43]. The
frequency with which it causes disease is reliably estimated from
annual surveillance data collected by the National Nosocomial
Infection Surveillance (NNIS) system of the Centers for Disease
Control and Prevention (CDC). According to these data, col-
lected between 1986 and 1998, P. aeruginosa was the second
most common cause of nosocomial pneumonia (14% of iso-
lates), the third most common cause of urinary tract infection
(7%), the fourth most common cause of surgical site infection
(8%), the seventh most frequently isolated pathogen from the
bloodstream (2%), and the fifth most common isolate (9%)
overall from all sites [14]. Patients with cystic fibrosis, neutro-
penia, or multiple devices are at the greatest risk of P. aeruginosa
infection [10, 17, 18, 33, 37, 44–55].
Because of the prevalence of P. aeruginosa in the hospital
environment, epidemiological investigation for discrete out-
breaks is facilitated by the use of markers that discriminate
among strains [32]. The most specific and sensitive epidemi-
ological tool identified to date is molecular characterization of
the strains [25, 45, 52, 56–61].
In this study we determined the frequencies of occurrence
of P. aeruginosa (including MDR-PSA) as a reported pathogen,
by geographic region and body site; the antimicrobial profiles
of isolates were also studied. The SENTRY Antimicrobial Sur-
veillance Program is a longitudinal surveillance study designed
to track antimicrobial resistance trends nationally and inter-
nationally over a 5- to 10-year period. This report also includes
evaluations of the antimicrobial activity of diverse antimicro-
bials against MDR-PSA strains and the molecular characteri-
zations of P. aeruginosa strains.
MATERIALS AND METHODS
Study design. The SENTRY Antimicrobial Surveillance Pro-
gram monitored the predominant pathogens and antimicrobial
resistance patterns of nosocomial and community-acquired in-
fections via a broad network of sentinel hospitals in 4 major
world regions: Asia-Pacific, Europe, Latin America, and the
United States/Canada. The monitored infections include blood-
stream infections (objective A), outpatient respiratory infec-
tions due to fastidious organisms (objective B), pneumonia
(objective C), skin/soft-tissue infections (objective D), and uri-
nary tract infections (objective E). Consecutive isolates (540
strains/year for all objectives per laboratory) were forwarded
to the regional monitors for confirmation of organism iden-
tification and susceptibility testing. Since most of the isolates
are collected from nonsterile body sites, the participating med-
ical centers are encouraged to send clinically significant isolates.
Just 1 isolate per patient was included in this study. A summary
description of demographic data such as each patient’s age, sex,
ward, hospitalization in the intensive care unit, and type of
infection (nosocomial or community-acquired) was also
obtained.
Participating medical centers. The number of participat-
ing medical centers ranged from 66 laboratories in 1997 to a
high of 81 sites in 1998. The participants varied slightly in
number by year in the following regions: 5–8 sites in Canada,
26–28 in the United States, and 12–23 in Europe, Israel, and
Turkey combined. The number of sites remained constant in
the Asia-Pacific region (17 sites) and Latin America (10 sites).
Technicians at 3 reference laboratories, using common reagents
and methodologies, evaluated the respective isolates. These lab-
oratories were located at the University of Iowa College of
Medicine, in Iowa City, Iowa (for isolates from Canada, the
United States, and Latin America for 1997–1999 and Europe
for 1999); Women’s and Children’s Hospital, in Adelaide, Aus-
tralia (for isolates from the Asia-Pacific region for 1998–1999);
and Utrecht University, in Utrecht, the Netherlands (for isolates
from Europe for 1997–1998).
Bacterial strains. A total of 70,067 bacterial isolates were
collected between January 1997 and December 1999. This num-
ber did not include isolates collected from objective B. Isolates
collected from urinary tact and skin/soft-tissue infections in Can-
ada, Europe, and the United States during 1999 also were not
included because of a change in the protocol. During the study
period, 6631 P. aeruginosa isolates were collected. The distribu-
tion of isolates by region was as follows: Asia-Pacific, 757; Can-
ada, 580; Europe, 1659; Latin America, 1132; and the United
States, 2498. Isolates for which MICs were high (piperacillin,164
mg/mL; ceftazidime, 116 mg/mL; imipenem, 18 mg/mL; and gen-
tamicin, 18 mg/mL) were classified as multidrug-resistant (MDR)
isolates.
Organism identification. All isolates were identified at the
participating institution by the routine methodology in use at
each laboratory. Upon receipt at the monitoring laboratory,
isolates were subcultured onto blood agar to ensure viability
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Table 1. Geographic variation in the occurrence of infections caused by Pseudomonas
aeruginosa in the SENTRY Antimicrobial Surveillance Program (1997–1999).
Country or region
Occurrence by site of infection: total no. of isolates,
% P. aeruginosa (rangea)
Blood Respiratory Wound Urine
Asia-Pacific 3162 1704 791 959
4.5 (4.4–4.7) 23.4 (22.1–26.0) 13.8 (10.8–14.8) 11.0 (10.0–12.9)
Canada 3840 1659 633 651
4.3 (3.6–4.9) 17.6 (16.3–18.8) 12.0 (11.8–12.1) 7.5 (7.3–7.6)
Europe 10,815 2572 2305 2135
5.6 (5.3–6.3) 22.2 (20.4–26.8) 14.0 (13.3–14.7) 7.3 (6.2–8.5)
Latin America 5295 1914 1353 1430
6.5 (5.6–7.7) 25.0 (21.6–26.9) 11.5 (9.4–12.4) 8.0 (7.4–9.1)
United States 17,399 6711 2191 2569
4.4 (4.2–4.6) 19.3 (18.2–20.4) 11.9 (10.9–12.9) 6.7 (5.8–7.5)
NOTE. A total of 70,067 strains (6631 P. aeruginosa isolates) were analyzed over the 3-year study
period.
a Range indicates occurrence rates over the 3 study years.
and purity. Species identifications were confirmed with the Vi-
tek system (bioMe´rieux Vitek) or conventional methods as re-
quired [1].
Susceptibility testing. At the monitoring laboratory, an-
timicrobial susceptibility testing was performed with the ref-
erence broth microdilution method, as described by the Na-
tional Committee for Clinical Laboratory Standards [62]. The
MICs were defined as the lowest antibiotic concentrations able
to inhibit bacterial growth. Antimicrobial agents were obtained
from the respective manufacturers. They included aztreonam,
piperacillin, piperacillin-tazobactam, ceftazidime, cefepime,
imipenem, meropenem, ciprofloxacin, levofloxacin, gatifloxa-
cin, trovafloxacin, amikacin, gentamicin, tobramycin, tetracy-
cline, and trimethoprim-sulfamethoxazole. Quality control was
performed by testing Escherichia coli American Type Culture
Collection (ATCC) 25922, Staphylococcus aureus ATCC 29213,
P. aeruginosa ATCC 27853, Enterococcus faecalis ATCC 29212,
Haemophilus influenzae ATCC 49247, and Streptococcus pneu-
moniae ATCC 49619.
Molecular study. The P. aeruginosa isolates were selected
for typing by ribotypes if they were recovered during a short
period of time at a single center and had similar antibiograms.
Ribotyping was performed with the RiboPrinter Microbial
Characterization system (E.I. duPont de Nemours) according
to the manufacturer’s instructions. In brief, colonies were
picked from individual culture plates and streaked for growth
on brain-heart infusion plates. Cells were suspended in lysis
buffer, lysing enzymes were added, and the tubes were placed
in the RiboPrinter. Within the RiboPrinter, bacterial cells were
lysed, the DNA was digested with Pvu II, and the restriction
fragments were separated by electrophoresis and transferred to
nylon membranes. A chemiluminescent-labeled DNA probe
containing the rRNA operon (rrnB) from E. coli was hybridized
to the DNA on the membrane. The patterns were electronically
imaged, stored, and compared. Pattern comparisons were based
on both position and signal intensity. Isolates with coefficients
of similarity 10.9 were considered to have the same ribotype
profile [52].
RESULTS
Frequency of occurrence of P. aeruginosa as a reported path-
ogen, by geographic region and body site. During the 3-year
period (1997–1999), SENTRY participants reported a total of
70,067 strains, of which 6631 were P. aeruginosa. Table 1 lists
the geographic distribution of infections caused by P. aerugi-
nosa, classified by site of infection. There was considerable ge-
ographic variation in the rates of isolation of P. aeruginosa, and
the highest figures across all sites of infection were recorded in
the Asia-Pacific region and Latin America (11.4%; data not
shown), followed by Europe (9.3% of isolates), the United
States (8.7%), and Canada (8.6%). The difference was statis-
tically significant for P. aeruginosa isolations in Latin America
or the Asia-Pacific region versus those in Europe or North
America ( ). However, the difference found between theP ! .001
rates in Europe and Canada or the United States was not sta-
tistically significant ( ).Pp .092
The distribution or rank order of P. aeruginosa isolates by
body site was generally the same for all regions evaluated: the
respiratory tract was the most frequent source of P. aeruginosa
isolates, followed by wounds, urine, and bloodstream. However,
some regions contributed more P. aeruginosa isolates from a
specific site than other geographic areas. As an example, Latin
America and Europe showed the highest proportion of P. aeru-
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Table 2. Trends in antimicrobial susceptibility of all Pseudomonas aeruginosa isolates according to monitored region, during 1997,
1998, and 1999 (SENTRY Antimicrobial Surveillance Program).
Antimicrobial agent
Percentage of isolates susceptiblea
Asia-Pacific Canada Europe Latin America United States
1998 1999 1997 1998 1999 1997 1998 1999 1997 1998 1999 1997 1998 1999
b-Lactams
Aztreonam 66.5 65.3 73.4 67.1 75.2 80.2 73.2 55.6a 55.5 45.0 48.2 67.0 64.7 62.3
Piperacillin 85.5 85.8 91.7 87.4 89.1 85.6 77.0 73.8b 71.9 66.7 67.5 87.9 87.3 83.7c
Piperacillin/tazobactam 90.2 87.5 93.2 90.4 95.6 90.1 77.0 73.8b 79.4 77.1 74.9 89.9 89.9 86.6a
Ceftazidime 76.1 83.7d 80.2 80.2 84.7 85.1 78.2 71.6a 66.6 64.4 66.9 79.5 81.2 78.1
Cefepime 81.6 85.8 80.2 84.4 91.2c 80.8 83.0 73.8c 66.2 67.9 66.3 77.7 85.8 83.1b
Imipenem 90.0 86.2 83.0 82.0 92.0c 89.3 79.0 71.6a 77.0 76.7 74.3 88.0 85.2 80.9
Meropenem 91.5 87.8 92.4 91.6 94.9 89.8 85.6 73.8a 83.0 79.7 76.6b 92.4 90.8 90.9
Aminoglycosides
Amikacin 94.2 95.8 91.4 95.8 97.8c 89.0 86.8 78.9c 77.6 73.3 69.5c 95.0 94.8 96.6
Tobramycin 88.5 89.9 91.4 93.4 94.2 76.3 78.3 68.4c 68.1 64.9 64.2 91.1 92.7 92.2
Quinolones
Ciprofloxacin 84.8 83.7 79.9 74.3 81.0 73.5 73.8 67.6 67.2 60.8 60.9 79.8 77.9 75.36
Levofloxacin 83.8 82.6 74.5 70.1 80.3 71.1 73.4 68.4 63.6 59.0 59.5 74.4 73.7 73.4
Gatifloxacin 80.1 77.5 66.2 64.1 74.5 72.0 72.2 64.0 60.9 57.1 56.8 69.1 69.0 67.2
Trovafloxacin 84.8 82.0 76.6 74.1 81.0 70.6 73.9 68.4 65.4 60.1 60.7 75.2 77.4 73.7
Tetracyclines 2.6 4.2 2.9 3.0 2.9 6.8 4.7 2.2c 1.2 1.7 1.8 2.7 2.3 3.5
NOTE. Susceptibility was determined with use of the National Committee for Clinical Laboratory Standards criteria published in 2000. The footnotes indicate
statistical significance. between values for the indicated years.P ! .5
a Over the 3-year study period.
b Between 1997 and 1998 as well as 1997 and 1999.
c Between 1997 and 1999.
d Between 1998 and 1999.
ginosa strains among the consecutive blood isolates submitted.
If the data from participating centers are representative of the
national picture or are matched, this may indicate higher rates
of P. aeruginosa bacteremia in these areas. Latin America, the
Asia-Pacific region, and Europe had the highest rates of re-
covery among respiratory isolates; isolation rates in the United
States were consistently below these except for urinary tract
isolations. This may reflect greater use of indwelling urinary
tract catheters in the United States, since this organism is rarely
a primary urinary tract pathogen. The occurrence rates of P.
aeruginosa over the 3 years were similar among different body
sites in the United States and Canada. However, a higher var-
iation in the ranges of respiratory isolations in the Asia-Pacific
region, Latin America, and Europe was observed. These regions
contributed more respiratory isolates in 1998 than in other
years. Moreover, in the Asia-Pacific region, the number of
wound isolates collected in 1998 was nearly 4 times higher than
in 1999.
Trends in antimicrobial susceptibility patterns. The anti-
microbial susceptibilities of P. aeruginosa isolates during the
study period are shown in table 2. Several differences in anti-
microbial susceptibilities, indexed by geographic regions, were
observed. Overall, Latin American isolates showed the lowest
susceptibility rate to all antimicrobial agents tested, followed
by Asia-Pacific isolates (to b-lactams) and European strains (to
the fluoroquinolones). Canada had the best global susceptibility
testing results (low levels of resistance). Amikacin was the an-
timicrobial agent associated with the highest susceptibility rate,
in all regions except Latin America. On the other hand, Europe
was the only region in which there was a significant decline in
the b-lactam and aminoglycoside susceptibility rates over the
3 monitored years. This fact cannot be explained by the later
inclusion of Turkish sites, where MDR-PSA are present, since
they replaced a Portuguese and an Italian site, where MDR-
PSA were also frequently observed.
With respect to carbapenem susceptibility, 3 regions had in-
creased resistance rates: there was a reduction in susceptibility
of Canadian isolates to imipenem, of Latin American isolates
to meropenem, and of European isolates to both imipenem
and meropenem. Imipenem has probably acted as the selective
agent (source of selective pressure), since in most countries
meropenem has only recently become commercially available
or its use has been severely restricted.
It is notable that Latin America had the lowest rates of sus-
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Table 3. Occurrence of the 218 multidrug-resistant Pseu-
domonas aeruginosa (MDR-PSA) strains, by body site of
isolation. Data were obtained from participant medical cen-




Occurrence by site of infection:
no. of MDR-PSA isolates
(no. of medical centersa)
Blood Respiratory Wound Urine
Asia-Pacific
1997 (n p 8) 1 (1) 2 (2) 5 (3) 0
1998 (n p 7) 1 (1) 6 (1) 0 0
Canada
1997 (n p 3) 0 3 (2) 0 0
1998 (n p 2) 0 1 (1) 0 1 (1)
1999 (n p 0) 0 0 0 1 (1)
Europe
1997 (n p 6) 3 (2) 1 (1) 1 (1) 1 (1)
1998 (n p 48) 19 (8) 15 (5) 12 (4) 2 (2)
1999 (n p 24) 5 (4) 16 (5) 2 (1) 1 (1)
Latin America
1997 (n p 23) 3 (3) 13 (5) 4 (2) 3 (2)
1998 (n p 31) 10 (4) 16 (4) 2 (2) 3 (3)
1999 (n p 36) 11 (3) 11 (5) 7 (3) 7 (2)
United States
1997 (n p 12) 2 (2) 7 (4) 2 (1) 1 (1)
1998 (n p 8) 0 4 (4) 1 (1) 3 (2)
1999 (n p 10) 3 (3) 6 (4) 0 1 (1)
NOTE. P. aeruginosa isolates were defined as multiresistant (MDR-
PSA) if they were resistant to piperacillin (MICs, 164 mg/mL), ceftazi-
dime (116 mg/mL), imipenem (18 mg/mL), and gentamicin (18 mg/mL).
a This indicates the number of medical centers contributing MDR-
PSA in the respective region.
Figure 1. Distribution of multidrug-resistant Pseudomonas aeruginosa
isolates, according to the ages of the patients from whom they were
recovered, in Latin America (white bars) and the United States (black
bars).
ceptibility to ceftazidime and cefepime and also the highest
increase in susceptibility rate, when tazobactam was associated
with piperacillin. This observation raises the hypothesis that
extended-spectrum b-lactamase (ESBL) production could be
one of the mechanisms of resistance shared by P. aeruginosa
against broad-spectrum cephalosporins, since high rates of
ESBL-producing Klebsiella pneumoniae strains have been noted
in most of the participating Latin American centers. Increased
cefepime susceptibility rates were observed in Canada and the
United States, perhaps because overexpression of AmpC en-
zymes may be an important resistance mechanism in such iso-
lates. In contrast, an elevation in the rate of susceptibility to
ceftazidime, but not to cefepime, was seen in the Asia-Pacific
region. Decreases in piperacillin and piperacillin/tazobactam
susceptibility rates, at statistically significant levels, were ob-
served only in Europe and the United States.
With regard to the resistance situation as a whole, a reduction
in fluoroquinolone susceptibility rates was noted in the 3-year
study, but a reduction in susceptibility at statistically significant
levels was observed only in the United States. However, with
ciprofloxacin being the most potent currently available agent,
the 60.9% susceptibility rate in Latin America and the 67.6%
rate in Europe denote major problems.
MDR-PSA. MDR-PSA isolates (218 strains), defined as
being resistant to piperacillin, ceftazidime, imipenem, and gen-
tamicin, were selected for analysis. Their distribution by geo-
graphic region and body site is shown in table 3. The respiratory
tract was still the most frequent site of isolation (101 of 218
isolates; 46.1%), and the bloodstream was the second most
frequent source of MDR-PSA isolates. Latin America was the
region with the greatest number of MDR-PSA isolates (90).
The rates of occurrence of MDR-PSA by geographic region
were as follows: Latin America, 8.2%; Europe, 4.7%; United
States, 1.2%; Asia-Pacific, 1.6%; and Canada, 0.9%. Approxi-
mately 56% of MDR-PSA strains isolated in Latin America were
collected from just 1 Brazilian medical center. If this site were
excluded, the frequency of occurrence of MDR-PSA in Latin
America would be reduced to only 3.6%, i.e., less than the rate
recorded for Europe.
Two medical centers in the Asia-Pacific region, 1 in China
and another in the Philippines, contributed more MDR-PSA
isolates than other sites, and an outbreak could not be excluded.
A similar situation occurred in Europe, where a Portuguese
facility and an Italian medical center isolated 20.0% and 16.4%,
respectively, of the total number of MDR-PSA strains in 1998,
and 2 Turkish sites each isolated 16.4% of the total number in
1999. In contrast, most of the MDR-PSA samples in Canada
and the United States were isolated in diverse medical centers,
and endemic strains were not discovered in the US or Canadian
centers evaluated by SENTRY.
Eleven antimicrobial agents were tested against MDR-PSA
isolates (table 4). Overall susceptibility rates were very low, and
aminoglycosides were the most active antimicrobial class, al-
though they inhibited one-half of MDR-PSA strains only in
the United States. MDR-PSA strains isolated in Europe were
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Table 4. Antimicrobial activity of 11 antimicrobial agents tested against 218 multidrug-resistant
Pseudomonas aeruginosa isolates in the SENTRY Antimicrobial Surveillance Program (1997–1999).
Agent tested












Aztreonam 116 (0) 116 (20.0) 116 (10.1) 116 (0) 116 (0)
Piperacillin/tazobactam 164 (6.6) 164 (0) 164 (12.6) 164 (7.8) 164 (13.3)
Cefepime 116 (0) 116 (0) 116 (1.3) 116 (1.1) 116 (13.3)
Meropenem 18 (0) 8 (40.0) 18 (0) 18 (3.3) 18 (0)
Aminoglycosides
Amikacin 32 (33.3) 32 (20.0) 132 (19.0) 132 (12.2) 16 (50.0)
Tobramycin 16 (0) 8 (40.0) 116 (3.8) 116 (3.8) 116 (20.0)
Quinolones
Ciprofloxacin 12 (13.3) 12 (20.0) 12 (2.5) 12 (6.6) 12 (3.3)
Gatifloxacin 14 (13.3) 14 (0) 14 (3.8) 14 (3.3) 14 (6.6)
Levofloxacin 14 (13.3) 14 (0) 14 (5.0) 4 (7.7) 14 (10.0)
Trovafloxacin 14 (13.3) 14 (20.0) 14 (3.8) 14 (10.0) 14 (6.6)
Tetracyclines 18 (0) 18 (0) 18 (0) 18 (0) 18 (6.6)
NOTE. P. aeruginosa isolates were defined as multiresistant if they were resistant to piperacillin (MICs, ≥128
mg/mL), ceftazidime (116 mg/mL), imipenem (18 mg/mL), and gentamicin (18 mg/mL). MICs were determined by broth
microdilution. Susceptibility was determined with use of the National Committee for Clinical Laboratory Standards
criteria published in 2000.
a n, no. tested.
less susceptible to fluoroquinolones than in other regions, and
b-lactams had little activity against MDR-PSA in any region,
as expected on the basis of the definition of MDR-PSA. It is
remarkable that no therapeutic agent that was routinely tested
inhibited 150% of MDR-PSA strains, since there are few op-
tions for treatment against such microbes. Eighty bloodstream
P. aeruginosa isolates in 1998 were tested with polymyxin B and
colistin (data not shown), and none of the strains were resistant;
therefore, polymyxins may be an alternative for treatment
against MDR-PSA, although these compounds are considerably
toxic and have poor distribution profiles.
MDR-PSA demographic information. Figure 1 shows the
distribution of MDR-PSA isolates according to age, in both
Latin America and the United States. Most MDR-PSA strains
(56%) occurred in patients 151 years of age in Latin America;
64% were males, and 90% of the infections were nosocomial.
In the United States, 57% of MDR-PSA isolates were recovered
from male patients, and 23% of isolations occurred between
the ages of 61 and 70 years; a second peak occurred between
31 and 40 years of age (20% of isolates). In contrast to cases
in Europe and Latin America, only 3.3% of cases occurred in
patients 171 years of age. In Europe, 80% of the infections
were nosocomial, and the greatest number of cases (50%) oc-
curred in intensive care units, followed by internal medicine
units (28%). More than 80% of patients in Europe needed
intensive care during hospitalization. In contrast to the United
States and Latin America, where infections in the very young
were rare, 24% of the MDR-PSA infections in Europe occurred
in patients !10 years old.
Molecular characterization. Molecular characterizations
of isolates that were recovered within a short time at the same
center and that had the same susceptibility patterns are shown
in table 5. During the study period, 118 strains were selected
for typing from the surveillance program. No isolates from the
Asia-Pacific region were ribotyped. It is remarkable that isolates
with unique ribotypes were found in Europe, Latin America,
and the United States. On the other hand, ribogroup 566-6 was
identified in samples collected from 3 SENTRY geographic
regions: Europe, Latin America, and the United States. The
samples were collected at 2 different sites in Argentina (3 and
4 isolates), 1 site in Colombia (1 isolate), 1 site in France (1
isolate), 1 site in Turkey (3 isolates), and 4 sites in the United
States (6 isolates). All the European and US isolates belonging
to this ribogroup (566-6) were collected from the respiratory
tract.
Another common ribogroup, 798-3, was identified in Europe
and the United States and also involved only respiratory iso-
lates. The isolates were collected at 2 sites in Turkey and 2 in
the United States. Just 1 ribogroup (560-7) was found in com-
mon among Canada, Latin America, and the United States,
whereas Europe and Latin America shared 3 common ribo-
groups: 1033-3, at 2 sites in Argentina, 1 in Brazil, and 1 in
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Table 5. Molecular characterization by automated ribotyping of Pseudomonas aeruginosa strains
selected from the SENTRY Antimicrobial Surveillance Program between 1997 and 1999.
Ribotype
No. of strains (no. of medical centersa)
Canada Europe Latin America United States Blood Respiratory Wound Urine
559-4 0 0 17 (2)b 0 1 (1) 10 (2) 4 (1) 2 (1)
560-7 2 (1) 0 1 (1) 1 (1) 0 2 (1) 1 (1) 1 (1)
566-6 0 4 (2)b 8 (3)b 6 (4) 5 (2) 10 (6) 1 (1) 2 (2)
676-7 1 (1) 0 0 1 (1) 0 1 (1) 0 1 (1)
798-3 0 6 (2)b 0 4 (2) 0 10 (4) 0 0
1005-1 0 0 10 (2)b 0 2 (1) 7 (2) 1 (1) 0
1033-3 0 2 (1) 7 (3) 0 3 (1) 3 (1) 1 (1) 2 (1)
1034-5 0 2 (1) 1 (1) 0 1 (1) 2 (1) 0 0
1034-6 0 0 2 (1) 0 2 (1) 0 0 0
1161-1 0 3 (1) 1 (1) 0 1 (1) 3 (1) 0 0
1161-3 0 2 (1) 0 0 0 2 (1) 0 0
1163-4 0 0 0 2 (1) 2 (1) 0 0 0
1342-7 0 0 2 (1) 0 0 2 (1) 0 0
Unique 0
Unique 6 (4) 5 (4) 1 (1)
Unique 13 (5) 2 (2) 4 (3) 4 (4) 3 (3)
Unique 15 (7) 0 11 (4) 0 4 (3)
NOTE. The isolates were selected for typing only if they were recovered during a short period at a single center and
displayed similar, usually resistant antibiograms.
a Number of centers that had MDR-PSA isolates with the respective ribotype number.
b Ribotype grouping clusters discovered at a single medical center.
Israel; 1034-5, at 1 site in Brazil and 1 in Turkey; and 1161-1,
at 1 site in Argentina and 1 in Turkey. The isolates belonging
to these ribogroups were recovered from diverse body sites.
Ribogroups 559-4 and 1005-1 were detected in 2 different
Brazilian sites, but 1 of them contributed only 2 strains, 1 of
each ribogroup. This situation clearly shows the presence of
epidemic/endemic clones in 1 of the Brazilian sites. This re-
spective site did not share ribogroups with any other facilities
in Canada, Europe, or the United States. Further studies
(pulsed-field gel electrophoresis) were performed and con-
firmed the dissemination of epidemic clones within medical
centers in Europe (2 ribotypes; 2 sites each) and Latin America
(3 ribotypes; 2 or 3 sites each [table 5]).
DISCUSSION
P. aeruginosa is a leading cause of nosocomial infections, rank-
ing second among the gram-negative pathogens reported to the
NNIS [2, 14, 63]. There are a limited number of antimicrobial
agents with reliable activity against P. aeruginosa, including an-
tipseudomonal penicillins and cephalosporins, carbapenems,
aminoglycosides, and fluoroquinolones. Resistance to antimi-
crobials is an increasing clinical problem and is a recognized
public health threat [64]. P. aeruginosa shows a particular pro-
pensity for the development of resistance, and this situation is
associated with increased rates of mortality and morbidity and
higher costs [65]. We conducted this study to assess the oc-
currence of P. aeruginosa infections in relation to body sites
and geographic regions. We also studied resistance arising over
a 3-year period in each geographic region.
A large number of isolates were contributed by several centers
in different geographic areas. As expected, a decrease in the
susceptibility of P. aeruginosa was seen over the 3-year period
in all the geographic regions studied. This decrease was more
evident for b-lactams in Europe, for piperacillin (alone or with
tazobactam) in the United States, for aminoglycosides in Eu-
rope and Latin America, and for ciprofloxacin in the United
States. The rates of occurrence of MDR-PSA between 3.6% and
7.7% were similar to those obtained in other series [14–16, 49,
53, 54, 66–70]. Rates of occurrence in bloodstream infections
in Canada and the United States in 1999 were slightly higher
than in previous studies that ended in 1998; this agrees with
the increasing trend described above. Our rates of resistant
isolates were greater than those described earlier [71], perhaps
because in our study isolates from sites other than the blood-
stream, which are more resistant, were included.
It is clear that surveillance programs are necessary to identify
changes in the spectrum of pathogens causing serious infections
and to monitor trends in antimicrobial susceptibility patterns.
The information obtained from such studies is necessary to
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design empirical approaches to therapy for infections and to
guide formulary practices.
It is remarkable that there are considerable differences among
isolates in different geographic regions. The reasons for these
differences in antimicrobial susceptibility are generally unclear
but may be due to differences in antimicrobial utilization prac-
tices and the quality of infection control practices or public
health infrastructures.
One important finding of this study is that no single em-
pirical therapy ensures a successful microbiological outcome
against 190% of P. aeruginosa infections worldwide. In the Asia-
Pacific region only aminoglycosides reach this target number
(190%) in empirical therapy; in Canada, several b-lactams and
aminoglycosides reach this level. Europe and Latin America
show the most disturbing trends in the efficacy of empirical
therapy: no agent inhibits 80% of the strains. Resistance in the
United States is similar to that seen in the Asia-Pacific region
for most agents. Ciprofloxacin, the most potent agent available
in oral form for treatment of P. aeruginosa infections, is in
particular jeopardy: in Europe, the United States, and Latin
America, rates of susceptibility to the drug are between 60%
and 75%. The eventual loss of this agent may mean that the
treatment of all Pseudomonas infections will require injectable
therapy and possibly hospitalization, a clear example of the
increased costs associated with resistance [65].
Independent of the controversy that concerns the need for
monotherapy versus combination therapy for P. aeruginosa in-
fections, antimicrobial resistance of P. aeruginosa has reached
a level in most regions of the world such that empirical therapy
against this organism may require the initial use of 2 or more
agents, until susceptibility testing results are known. Resistance
levels will continue to increase unless measures are taken to
curtail this rise. Combinations will suffice only for empirical
therapy; they have not been shown to definitively reduce the
development of resistance against modern b-lactams, and there
is a risk that this approach could encourage resistance to both
agents. Moreover, MDR-PSA are increasingly being isolated [17,
72–75], and against some isolates the only therapeutic option
is polymyxins, which have poor pharmacokinetic profiles and
considerable toxicity [30, 40, 56, 76].
No new classes of antimicrobials active against P. aeruginosa
will be available for therapy within the next 5–7 years. Most
new quinolones in development are likely to show some degree
of cross-resistance to ciprofloxacin. Much attention has been
paid to increasing resistance among Enterobacteriaceae or
gram-positive cocci against b-lactams, but these investigations
suggest that resistance of P. aeruginosa may be a greater threat
for hospitalized patients, especially since this organism is
thought to be associated with the highest attributable mortality
among gram-negative bacteria.
In conclusion, ongoing surveillance of microbial pathogens
and their resistance profiles is important [74, 77] to guide future
antimicrobial chemotherapy and the development of anti-
microbial agents. The SENTRY program will continue its sur-
veillance of both nosocomial and community-acquired serious
infections. The findings of these surveillance studies will en-
hance our knowledge regarding the problem of antimicrobial
resistance and will serve as a basis for future policies and prac-
tice styles.
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